drugset
drugset / Trial / NCT04728724

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

NCT04728724 ↗

Phase 2 Recruiting 100 enrolled Shanghai Pulmonary Hospital, Shanghai, China
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a phase II, non-randomized, open-label, multi-center study to evaluate the efficacy of neoadjuvant Sintilimab (PD-1 antibody) or combined with chemotherapy as first-line treatment in patients with stage III non-small cell lung cancer (NSCLC).

Timeline

Start
2022-09-10
Primary completion
2023-09-15
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Paclitaxel Small molecule 200 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

non-small cell lung carcinoma